170 related articles for article (PubMed ID: 31398627)
1. Quantification of coagulation factor VIII in human plasma with liquid chromatography tandem mass spectrometry using a selective sample purification with camelid nanobodies.
El Amrani M; Donners AAM; Graat G; Lentjes EG; Huisman A; Musson REA; van Maarseveen EM
J Pharm Biomed Anal; 2019 Oct; 175():112781. PubMed ID: 31398627
[TBL] [Abstract][Full Text] [Related]
2. Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle.
Donners AAMT; van Maarseveen EM; Weetink YRJ; El Amrani M; Fischer K; Rademaker CMA; Egberts TCG; Huisman A; Musson REA
Int J Lab Hematol; 2020 Dec; 42(6):819-826. PubMed ID: 32633067
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
4. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors.
D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L
Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645
[TBL] [Abstract][Full Text] [Related]
5. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
6. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
7. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
8. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
9. Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII.
Rothschild C; Amiral J; Adam M; Meyer D
Haemostasis; 1990; 20(6):321-8. PubMed ID: 2129163
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry.
El Amrani M; Bosman SM; Egas AC; Hack CE; Huitema ADR; van Maarseveen EM
Ther Drug Monit; 2019 Oct; 41(5):640-647. PubMed ID: 31584927
[TBL] [Abstract][Full Text] [Related]
11. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
12. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
Pipe SW; Kaufman RJ
J Biol Chem; 1996 Oct; 271(41):25671-6. PubMed ID: 8810344
[TBL] [Abstract][Full Text] [Related]
13. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
14. Purification of factor VIII/von Willebrand factor from human plasma on immobilized lentil lectin.
Zhou FL; Burnouf-Radosevich M; Burnouf T
Protein Expr Purif; 1994 Apr; 5(2):138-43. PubMed ID: 8054845
[TBL] [Abstract][Full Text] [Related]
15. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII:C assay: influence of buffer components used in immunoaffinity chromatography for purification of factor VIII/von Willebrand factor.
Koops K; Hoff HS; Heethuis A; Das PC; Smit Sibinga CT
Thromb Res; 1994 May; 74(4):347-54. PubMed ID: 8085236
[TBL] [Abstract][Full Text] [Related]
17. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
[TBL] [Abstract][Full Text] [Related]
18. A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate.
Samor B; Michalski C; Brandin MP; Andre MH; Chtourou S; Tellier Z
Vox Sang; 2012 Jul; 103(1):35-41. PubMed ID: 22239246
[TBL] [Abstract][Full Text] [Related]
19. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
Kallas A; Kuuse S; Maimets T; Pooga M
Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
[TBL] [Abstract][Full Text] [Related]
20. The physiology and pathophysiology of the factor VIII complex.
Hamer RJ; Houdijk WP; Sixma JJ
Crit Rev Oncol Hematol; 1986; 6(1):19-54. PubMed ID: 3096583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
